PL3730136T3 - Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek - Google Patents

Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek

Info

Publication number
PL3730136T3
PL3730136T3 PL20163104.1T PL20163104T PL3730136T3 PL 3730136 T3 PL3730136 T3 PL 3730136T3 PL 20163104 T PL20163104 T PL 20163104T PL 3730136 T3 PL3730136 T3 PL 3730136T3
Authority
PL
Poland
Prior art keywords
treatment
kidney disease
chronic kidney
disease patients
ferric citrate
Prior art date
Application number
PL20163104.1T
Other languages
English (en)
Polish (pl)
Inventor
Enrique Poradosu
Ron BENTSUR
James F. OLIVIERO III
Original Assignee
Keryx Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals, Inc. filed Critical Keryx Biopharmaceuticals, Inc.
Publication of PL3730136T3 publication Critical patent/PL3730136T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/295Iron group metal compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL20163104.1T 2012-06-21 2013-06-21 Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek PL3730136T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261662565P 2012-06-21 2012-06-21
US201361757229P 2013-01-28 2013-01-28
US201361800618P 2013-03-15 2013-03-15
US201361801050P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PL3730136T3 true PL3730136T3 (pl) 2024-03-25

Family

ID=49769729

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20163104.1T PL3730136T3 (pl) 2012-06-21 2013-06-21 Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek

Country Status (19)

Country Link
US (3) US20130345303A1 (https=)
EP (3) EP3730136B1 (https=)
JP (4) JP2015535209A (https=)
KR (2) KR20200103855A (https=)
CN (2) CN113244209A (https=)
AU (2) AU2013278000A1 (https=)
BR (1) BR112014032049A2 (https=)
CA (1) CA2876982A1 (https=)
DK (1) DK3730136T3 (https=)
EA (1) EA201590062A1 (https=)
ES (2) ES2796254T3 (https=)
FR (1) FR25C1043I1 (https=)
HK (1) HK1214503A1 (https=)
IL (1) IL236356A0 (https=)
MX (1) MX2014015615A (https=)
NO (1) NO2025048I1 (https=)
PL (1) PL3730136T3 (https=)
SG (2) SG11201408521WA (https=)
WO (1) WO2013192565A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108938585A (zh) 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型
TWI653043B (zh) * 2012-12-20 2019-03-11 瑞士商伊蘭科動物健康公司 新用途
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
ES2856261T3 (es) * 2013-10-01 2021-09-27 Fresenius Medical Care Deutschland Gmbh Método y aparatos para determinar una pérdida diaria de hierro de un paciente
HK1223031A1 (zh) * 2013-11-04 2017-07-21 凯克斯生物制药公司 用於降低慢性肾病患者的心力衰竭的枸橼酸铁
WO2015110968A1 (en) * 2014-01-23 2015-07-30 Lupin Limited Pharmaceutical grade ferric citrate and method for its production
EP3157516A4 (en) 2014-06-22 2017-12-13 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
US20180071243A1 (en) * 2015-03-04 2018-03-15 Keryx Biopharmaceuticals, Inc. Use of ferric citrate in the treatment of iron-deficiency anemia
CN104688706B (zh) * 2015-04-01 2017-07-14 成都欣捷高新技术开发有限公司 一种高载药量、快速溶出的枸橼酸铁组合物及其制备方法
WO2016162794A1 (en) * 2015-04-08 2016-10-13 Leiutis Pharmaceuticals Pvt Ltd Pharmaceutical compositions of ferric citrate
WO2016162888A1 (en) * 2015-04-09 2016-10-13 Actavis Group Ptc Ehf. Process for preparing pharmaceutical grade ferric citrate
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
US20210085711A1 (en) 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019236639A1 (en) * 2018-06-04 2019-12-12 Tricida, Inc. Method of treating acid-base disorders
JP2022505697A (ja) 2018-10-29 2022-01-14 ファーマコスモス ホールディング エー/エス カルボキシマルトース第二鉄による鉄欠乏症の治療
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN117999069A (zh) 2021-05-27 2024-05-07 凯克斯生物制药公司 柠檬酸铁的儿科调配物
CN115024495B (zh) * 2022-06-27 2024-03-22 北京金康普食品科技有限公司 改善肾病患者钙磷代谢的营养组合物及其应用
WO2025181559A1 (en) * 2024-02-29 2025-09-04 Sloiron, Inc. Methods for determining the amount of encapsulated and free iron in a sample

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922461A4 (en) * 1996-07-19 2002-07-17 Nikken Chemicals Co Ltd MEDICINE AGAINST HYPERPHOSPHATANEMIA
US5753706A (en) * 1996-12-16 1998-05-19 Hsu; Chen Hsing Methods for treating renal failure
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
CN1600302A (zh) * 2003-09-22 2005-03-30 宝龄富锦生技股份有限公司 含有柠檬酸铁的医药组合物以及药用级柠檬酸铁及其制法和含有药用级柠檬酸铁的膳食营养品
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
NZ566743A (en) 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
EP1973549B1 (en) * 2006-01-06 2016-07-20 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP3066923B1 (en) * 2006-01-30 2025-11-05 Panion & BF Biotech Inc. Method of treating chronic kidney disease
CN108938585A (zh) * 2009-07-21 2018-12-07 凯克斯生物制药公司 柠檬酸铁剂型

Also Published As

Publication number Publication date
ES2796254T3 (es) 2020-11-26
EP3730136B1 (en) 2023-12-27
EP4335436A3 (en) 2024-05-15
US20140234416A1 (en) 2014-08-21
HK1214503A1 (zh) 2016-07-29
JP2015535209A (ja) 2015-12-10
EP2863906B1 (en) 2020-03-18
EP4335436A2 (en) 2024-03-13
IL236356A0 (en) 2015-02-26
CN113244209A (zh) 2021-08-13
WO2013192565A2 (en) 2013-12-27
AU2018203205B2 (en) 2020-03-12
KR20200103855A (ko) 2020-09-02
MX2014015615A (es) 2015-03-20
US20150079168A1 (en) 2015-03-19
JP2020100638A (ja) 2020-07-02
HK1210013A1 (en) 2016-04-15
SG10201805177PA (en) 2018-07-30
BR112014032049A2 (pt) 2017-07-25
JP2022070945A (ja) 2022-05-13
AU2013278000A1 (en) 2015-01-22
CA2876982A1 (en) 2013-12-27
US20130345303A1 (en) 2013-12-26
DK3730136T3 (da) 2024-01-22
KR102150135B1 (ko) 2020-08-31
EP2863906A2 (en) 2015-04-29
NO2025048I1 (no) 2025-11-06
ES2970050T3 (es) 2024-05-24
AU2018203205A1 (en) 2018-05-31
EA201590062A1 (ru) 2016-02-29
EP3730136A1 (en) 2020-10-28
WO2013192565A3 (en) 2015-10-15
JP2018138562A (ja) 2018-09-06
CN104884055A (zh) 2015-09-02
FR25C1043I1 (fr) 2026-01-02
KR20150036131A (ko) 2015-04-07
SG11201408521WA (en) 2015-01-29

Similar Documents

Publication Publication Date Title
IL236356A0 (en) Use of iron citrate to treat patients with chronic kidney disease
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
EP2890440A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
IL239007A0 (en) Use of Aribolin to treat breast cancer
GB201314512D0 (en) Dual Haemodialysis and Haemodiafiltration blood treatment device
IL237649B (en) Polymer meters drug for use in the prevention, diagnosis and/or treatment of diseases of the joint
SG10201709090UA (en) Sobetirome in the treatment of myelination diseases
EP2875158A4 (en) USE OF MICROVESICLES IN THE DIAGNOSIS, FORECAST AND TREATMENT OF DISEASES AND MEDICAL SUDDEN
IL230698A0 (en) Use of preparations containing crizotinib to treat cancer
SG11201603091QA (en) Ferric citrate for reducing cardiac failure in chronic kidney disease patients
HUE053156T2 (hu) Vegyületek agyi áttétek kezelésében történõ alkalmazásra ERBB2+ emlõrákos betegeknél
IL237765B (en) Treatment of vascular disease and its complications
HUS2000020I1 (hu) Ciklezonid a légúti betegségek kezelésére lovaknál
GB201207543D0 (en) Treatment of transfusion blood
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
SG11201601490XA (en) Risk markers for cardiovascular disease in patients with chronic kidney disease
ZA201404000B (en) Fluid-injection system for medical use in the vascular system of a patient
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
PT3007772T (pt) Composições para utilização no tratamento de dislipidemia em doença renal crónica
LT2702033T (lt) 3-karboksi-n-etil-n,n-dimetilpropan-1-amino druskos panaudojimas kardiovaskuliarinių ligų gydyme
PL2928461T3 (pl) Leczenie przewlekłej choroby nerek
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
ZA201307614B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease